Forging a new frontier in drug/device combination products

WESTBOROUGH, MA — (MARKET WIRE) — 06/23/2005 — Drug/device combination products are slated to hit $9.5 billion by 2009. This rapidly expanding market provides valuable opportunities to strategically diversify market reach and maximize product portfolios. Understanding the development and regulatory pathways is the challenge. To keep pace with this market, IBC has created a platform for research and business executives to collaborate on best practices and provide innovative products.

IBC’s conference on Drug/Device Combinations Products: Overcoming Development, Regulatory and Legal Hurdles to Gain Approval bring scientists and business executives together to address the growing regulatory requirements for combination products. The event is set for September 19-20, 2005, at the Hilton Minneapolis/St. Paul Hotel in Bloomington, Minnesota.

Conference highlights include:

— First-hand experience from industry professionals on how to meet the
challenges with development and commercialization efforts
— New tips and strategies from Vyteris and Genetronics highlighting the
development and commercialization of combination products
— Exploration of potential drawbacks associated with virtual product
— Identification of legal challenges for 505 (b) (2) applicants and how
to prepare for them

Drug/Device Combination Products is co-located IBC’s Medical Devices conference to help attendees network with colleagues and gain an edge in this increasingly competitive and dynamic market. A special keynote address from Jonathan Kahan, Esq., partner at Hogan and Hartson, on “New Development and Strategies for Device and Combination Product Clearances and Approvals” will address the combined conference audience.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.